These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 15515882

  • 1. Successful switch from inhalative iloprost to oral bosentan in portopulmonary hypertension associated with liver cirrhosis.
    Molnar C, Alber H, Colleselli D, Vogel W, Kähler CM.
    Wien Klin Wochenschr; 2004 Sep 30; 116(17-18):627-30. PubMed ID: 15515882
    [Abstract] [Full Text] [Related]

  • 2. Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentan.
    Halank M, Kolditz M, Miehlke S, Schiemanck S, Schmeisser A, Hoeffken G.
    Wien Med Wochenschr; 2005 Aug 30; 155(15-16):376-80. PubMed ID: 16160926
    [Abstract] [Full Text] [Related]

  • 3. Experience with inhaled iloprost and bosentan in portopulmonary hypertension.
    Hoeper MM, Seyfarth HJ, Hoeffken G, Wirtz H, Spiekerkoetter E, Pletz MW, Welte T, Halank M.
    Eur Respir J; 2007 Dec 30; 30(6):1096-102. PubMed ID: 17652314
    [Abstract] [Full Text] [Related]

  • 4. Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C.
    Grander W, Eller P, Fuschelberger R, Tilg H.
    Eur J Clin Invest; 2006 Sep 30; 36 Suppl 3():67-70. PubMed ID: 16919014
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of bosentan treatment for portopulmonary hypertension associated with syncope.
    Sato A, Maie K, Ohno Y, Yoshida T, Ito E, Tanabe Y, Aizawa Y.
    Int Heart J; 2011 Sep 30; 52(4):243-5. PubMed ID: 21828952
    [Abstract] [Full Text] [Related]

  • 6. Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension.
    Minder S, Fischler M, Muellhaupt B, Zalunardo MP, Jenni R, Clavien PA, Speich R.
    Eur Respir J; 2004 Oct 30; 24(4):703-7. PubMed ID: 15459152
    [Abstract] [Full Text] [Related]

  • 7. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy?
    Kuntzen C, Gülberg V, Gerbes AL.
    Gastroenterology; 2005 Jan 30; 128(1):164-8. PubMed ID: 15633133
    [Abstract] [Full Text] [Related]

  • 8. Bosentan therapy for portopulmonary hypertension.
    Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, Niedermeyer J, Winkler J.
    Eur Respir J; 2005 Mar 30; 25(3):502-8. PubMed ID: 15738295
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension.
    Austin MJ, McDougall NI, Wendon JA, Sizer E, Knisely AS, Rela M, Wilson C, Callender ME, O'Grady JG, Heneghan MA.
    Liver Transpl; 2008 Mar 30; 14(3):287-91. PubMed ID: 18306330
    [Abstract] [Full Text] [Related]

  • 10. Successful therapy of bosentan-refractory pulmonary arterial hypertension (PAH) with inhalative iloprost.
    Ahmadi-Simab K, Lamprecht P, Gross WL.
    Clin Exp Rheumatol; 2005 Mar 30; 23(3):402-3. PubMed ID: 15971433
    [Abstract] [Full Text] [Related]

  • 11. Endothelin-receptor antagonist treatment of portopulmonary hypertension.
    Hinterhuber L, Graziadei IW, Kähler CM, Jaschke W, Vogel W.
    Clin Gastroenterol Hepatol; 2004 Nov 30; 2(11):1039-42. PubMed ID: 15551258
    [Abstract] [Full Text] [Related]

  • 12. The impact of treatment of portopulmonary hypertension on survival following liver transplantation.
    Ashfaq M, Chinnakotla S, Rogers L, Ausloos K, Saadeh S, Klintmalm GB, Ramsay M, Davis GL.
    Am J Transplant; 2007 May 30; 7(5):1258-64. PubMed ID: 17286619
    [Abstract] [Full Text] [Related]

  • 13. Hemodynamic observations in two pulmonary hypertensive patients changing treatment from inhaled iloprost to the oral endothelin-antagonist bosentan.
    Fruhwald FM, Kjellström B, Perthold W, Wonisch M, Maier R, Klein W.
    J Heart Lung Transplant; 2005 May 30; 24(5):631-4. PubMed ID: 15896766
    [Abstract] [Full Text] [Related]

  • 14. Treatment with a combination of bosentan and sildenafil allows for successful liver transplantation in a patient with portopulmonary hypertension.
    Sağ S, Yeşilbursa D, Güllülü S.
    Turk J Gastroenterol; 2014 Aug 30; 25(4):429-32. PubMed ID: 25254528
    [Abstract] [Full Text] [Related]

  • 15. Successful treatment of portopulmonary hypertension with bosentan: case report.
    Stähler G, von Hunnius P.
    Eur J Clin Invest; 2006 Sep 30; 36 Suppl 3():62-6. PubMed ID: 16919013
    [Abstract] [Full Text] [Related]

  • 16. Secure Combination Therapy With Low-Dose Bosentan and Ambrisentan to Treat Portopulmonary Hypertension Minimizing Each Adverse Effect.
    Muraoka H, Imamura T, Hatano M, Maki H, Yao A, Kinugawa K, Komuro I.
    Int Heart J; 2015 Sep 30; 56(4):471-3. PubMed ID: 26084462
    [Abstract] [Full Text] [Related]

  • 17. Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol.
    Rafanan AL, Maurer J, Mehta AC, Schilz R.
    Chest; 2000 Nov 30; 118(5):1497-500. PubMed ID: 11083710
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension.
    Halank M, Miehlke S, Hoeffken G, Schmeisser A, Schulze M, Strasser RH.
    Transplantation; 2004 Jun 15; 77(11):1775-6. PubMed ID: 15201684
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.